CR20210661A - Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos - Google Patents
Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismosInfo
- Publication number
- CR20210661A CR20210661A CR20210661A CR20210661A CR20210661A CR 20210661 A CR20210661 A CR 20210661A CR 20210661 A CR20210661 A CR 20210661A CR 20210661 A CR20210661 A CR 20210661A CR 20210661 A CR20210661 A CR 20210661A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pyrazolopyrimidine
- jak kinases
- inhibitors
- jak
- sulfone inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
Abstract
En el presente documento se describen compuestos de fórmula (I) en los que R1 , R2 , R3 , R4 , R5 y R6 son como se definen en el presente documento, y sales de los mismos que son útiles como inhibidores de JAK cinasas. Además, se proporcionan composiciones farmacéuticas que incluyen dicho inhibidor de JAK y un portador, adyuvante o portador farmacéuticamente aceptable, y procedimientos para tratar o disminuir la gravedad de una enfermedad o afección sensible a la inhibición de la actividad de una Janus cinasa en un paciente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019091712 | 2019-06-18 | ||
US202063035381P | 2020-06-05 | 2020-06-05 | |
PCT/US2020/037853 WO2020257145A1 (en) | 2019-06-18 | 2020-06-16 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210661A true CR20210661A (es) | 2022-02-11 |
Family
ID=71575774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210661A CR20210661A (es) | 2019-06-18 | 2020-06-16 | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11453671B2 (es) |
EP (1) | EP3986901A1 (es) |
JP (1) | JP2022537964A (es) |
KR (1) | KR20220024405A (es) |
CN (1) | CN114008051A (es) |
AU (1) | AU2020297415A1 (es) |
BR (1) | BR112021025618A2 (es) |
CA (1) | CA3140024A1 (es) |
CL (1) | CL2021003341A1 (es) |
CO (1) | CO2022000118A2 (es) |
CR (1) | CR20210661A (es) |
IL (1) | IL288957A (es) |
MA (1) | MA56518A (es) |
MX (1) | MX2021015319A (es) |
PE (1) | PE20220577A1 (es) |
TW (1) | TW202115068A (es) |
WO (1) | WO2020257145A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023218484A1 (en) | 2022-05-11 | 2023-11-16 | Pi Industries Ltd. | Bicyclic compounds and their use as pest control agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
WO2003053930A1 (en) | 2001-12-20 | 2003-07-03 | Bayer Healthcare Ag | 1,4-dihydro-1,4-diphenylpyridine derivatives |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
WO2008094575A2 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases |
CN101616921A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
KR20110033223A (ko) | 2008-06-20 | 2011-03-30 | 제넨테크, 인크. | 트리아졸로피리딘 jak 억제제 화합물 및 방법 |
KR101686685B1 (ko) | 2008-10-31 | 2016-12-14 | 제넨테크, 인크. | 피라졸로피리미딘 jak 억제제 화합물 및 방법 |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
DK2917181T3 (da) | 2012-11-09 | 2020-01-13 | Medicines For Malaria Venture Mmv | Heteroarylderivater og anvendelser deraf |
WO2015177326A1 (en) | 2014-05-23 | 2015-11-26 | F. Hoffmann-La Roche Ag | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
JP6936236B2 (ja) | 2016-02-18 | 2021-09-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 治療化合物、組成物及びその方法の使用 |
CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
CN110494434B (zh) | 2017-03-14 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 吡唑并氯苯基化合物、其组合物及其使用方法 |
EP3630766A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018215390A1 (en) * | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2019139714A1 (en) * | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Pyrazolopyrimidine compounds as jak inhibitors |
US20200399274A1 (en) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof |
JP2022537354A (ja) | 2019-06-18 | 2022-08-25 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Jakキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用 |
-
2020
- 2020-06-16 BR BR112021025618A patent/BR112021025618A2/pt unknown
- 2020-06-16 CA CA3140024A patent/CA3140024A1/en active Pending
- 2020-06-16 MX MX2021015319A patent/MX2021015319A/es unknown
- 2020-06-16 JP JP2021574283A patent/JP2022537964A/ja active Pending
- 2020-06-16 AU AU2020297415A patent/AU2020297415A1/en not_active Abandoned
- 2020-06-16 CN CN202080044750.2A patent/CN114008051A/zh active Pending
- 2020-06-16 US US16/902,499 patent/US11453671B2/en active Active
- 2020-06-16 TW TW109120272A patent/TW202115068A/zh unknown
- 2020-06-16 WO PCT/US2020/037853 patent/WO2020257145A1/en unknown
- 2020-06-16 PE PE2021002182A patent/PE20220577A1/es unknown
- 2020-06-16 EP EP20739492.5A patent/EP3986901A1/en active Pending
- 2020-06-16 CR CR20210661A patent/CR20210661A/es unknown
- 2020-06-16 MA MA056518A patent/MA56518A/fr unknown
- 2020-06-16 KR KR1020227000044A patent/KR20220024405A/ko active Search and Examination
-
2021
- 2021-12-13 IL IL288957A patent/IL288957A/en unknown
- 2021-12-14 CL CL2021003341A patent/CL2021003341A1/es unknown
-
2022
- 2022-01-12 CO CONC2022/0000118A patent/CO2022000118A2/es unknown
- 2022-08-24 US US17/821,851 patent/US20230016791A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20220024405A (ko) | 2022-03-03 |
MX2021015319A (es) | 2022-04-07 |
US20200399275A1 (en) | 2020-12-24 |
CN114008051A (zh) | 2022-02-01 |
US11453671B2 (en) | 2022-09-27 |
TW202115068A (zh) | 2021-04-16 |
US20230016791A1 (en) | 2023-01-19 |
JP2022537964A (ja) | 2022-08-31 |
IL288957A (en) | 2022-02-01 |
WO2020257145A1 (en) | 2020-12-24 |
CA3140024A1 (en) | 2020-12-24 |
PE20220577A1 (es) | 2022-04-20 |
EP3986901A1 (en) | 2022-04-27 |
MA56518A (fr) | 2022-04-27 |
BR112021025618A2 (pt) | 2022-02-01 |
CL2021003341A1 (es) | 2022-07-22 |
AU2020297415A1 (en) | 2022-01-06 |
CO2022000118A2 (es) | 2022-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502601A1 (en) | Therapeutic compounds and compositions, and methods of use thereof | |
WO2017089390A8 (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
PH12015500666A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
TN2019000107A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
CA2983481A1 (en) | Janus kinase inhibitor | |
SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
WO2019169065A3 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
MY139689A (en) | Imidazotriazines as protein kinase inhibitors | |
WO2015194764A3 (ko) | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 | |
WO2016109217A3 (en) | Btk inhibitors | |
WO2014106800A3 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
PH12021551446A1 (en) | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 | |
MX2021013602A (es) | Inhibidores de jak. | |
CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
CA3173678A1 (en) | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders | |
CR20210364A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
CR20210661A (es) | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos |